Treatment and correction of presbyopia

Article

Initial experience with the new excimer laser SUPRACOR procedure

The treatment and correction of presbyopia continues to be a key area of clinical research, innovation and refinement in the field of refractive and cataract surgery. Accommodative solutions for presbyopia include the implantation of accommodating IOLs or the recovery of natural accommodation via sclera and lens manipulations.

However, the true mechanism of accommodation remains to be fully understood and real accommodative solutions are still under scientific investigation. Pseudoaccommodative techniques include the use of multifocal IOLs, pinhole and corneal inlays, or multifocal corneal approaches using excimer and femtosecond lasers.

An excimer-based technique

I have used a number of excimer-based approaches for treating presbyopia during the past 15 years. However, with these solutions, although providing the required multi-focality to afford psuedoaccommodation, there can be a compromise between achieving the optimal near and distance vision outcomes, which can lead to the induction of additional undesired aberrations within the pupil region. These unwanted aberrations can be caused by the surgically induced spherical aberrations or created by combining the near treatment with the distance correction, causing an overlap of the optical zones and transition zones. Overall, these aberrations can cause a loss of distance vision or quality of vision.

A new excimer-based algorithm, known as SUPRACOR, has been developed by Technolas Perfect Vision (TPV), which is designed to provide the near addition for treating presbyopia, while minimizing the induction of any undesired aberrations within the pupil region. This aberration-optimized presbyopic algorithm can be applied to a broad range of presbyopic patients, and may also be suitable for post-LASIK candidates as well. This treatment benefits from being a bilateral LASIK treatment approach, with the same profile applied to both eyes so there is no monovision. SUPRACOR can be performed on either the TECHNOLAS 217P or any TECHNOLAS excimer laser operating at 100 Hz and equipped with APT and the Advanced Control Eyetracking (ACE) technology.

Significant improvement in near vision

High level of Patient satisfaction

Effective and safe solution

As with all procedures, successful patient outcomes with the SUPRACOR procedure require a combination of both the right treatment algorithm and laser equipment and as well as appropriate patient management from the surgeon and clinic staff. Thorough patient selection, education and management should be applied preoperatively and postoperatively.

Further longer term follow-up data is required to confirm the stability of these outcomes, but according to the current data available, SUPRACOR certainly appears to provide an effective and safe solution to presbyopia, avoiding the previously reported compromises experienced with other excimer based algorithms, such as diminished distance vision. Because it is a bilateral treatment, it avoids any compromises associated with monovision. Furthermore, the treatment offers the option for easy enhancement and has the potential to be applied to post-LASIK patients. The SUPRACOR procedure received CE Mark approval in May 2011.

Dr Dominique Pietrini is an ophthalmologist at the Clinique de la Vision, Paris, France. He may be reached by E-mail: docteurpietrini@gmail.com

Dr Pietrini has indicated no financial interests in the subject matter of this article

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.